Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Ultarthin bronchoscopy with intratumoral washing: Each subject suspected of early-stage, resectable lung cancer will undergo bronchooscopic procedure. Ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Subsequently, intratumoral washing is performed. After undergoing surgery for suspected early-stage lung cancer, the analysis of next generation sequencing is conducted on intratumoral washing, tissue from surgical specimen, and blood.

Study summary

This is a single center, clinical trial evaluating the relevance of intratumoral washing for detection of generic alteration with Next Generation Sequencing.

Eligibility

Primary outcome measure(s)

• The diagnostic accuracy of genetic alterations in intratumoral washing fluid using Next Generation Sequencing — through study completion, an average of 1 year
  Diagnostic accuracy is defined as the number of true positive and true negative genetic alterations detected by Next Generation Sequencing, divided by the total number of intratumoral washing attempts using ultrathin bronchoscopy.

Trial sites (1)

More Pusan National University Hospital trials in South Korea

Other trials for the same condition